However, the contrasting clinical outcomes associated with CK5/6 and CK20 expression, assessed at the protein or at the mRNA levels, were frequently reported in early urothelial carcinoma of the upper or lower tract [6,19,20,21] and, occasionally, in MIBC [22]. The gene discussed is KRT5; the disease is urothelial carcinoma.